Incyte Corp
Company Profile
Business description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Contact
1801 Augustine Cut-Off
WilmingtonDE19803
USAT: +1 302 498-6700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,844
Stocks News & Analysis
stocks
ASX property share lifts guidance despite sector headwinds
stocks
Why stocks sometimes fall for no obvious reason
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,945.20 | 66.70 | 0.75% |
| CAC 40 | 8,215.22 | 42.11 | 0.52% |
| DAX 40 | 25,216.34 | 31.45 | 0.12% |
| Dow JONES (US) | 50,748.28 | 286.60 | 0.57% |
| FTSE 100 | 10,497.14 | 5.75 | 0.05% |
| HKSE | 25,328.23 | 271.22 | -1.06% |
| NASDAQ | 26,591.05 | 65.13 | -0.24% |
| Nikkei 225 | 64,999.41 | 3.32 | 0.01% |
| NZX 50 Index | 13,227.81 | 158.07 | 1.21% |
| S&P 500 | 7,514.04 | 5.08 | -0.07% |
| S&P/ASX 200 | 8,717.70 | 65.50 | 0.76% |
| SSE Composite Index | 4,093.73 | 51.65 | -1.25% |